Published in Medical Letter on the CDC and FDA, October 26th, 2008
"As we accelerate our sales process for Vytex(TM) NRL, our revolutionary latex-safe natural rubber latex (NRL) product, we are experiencing growth that requires a broader base of expertise on our board," Vystar President and Chief Executive Officer William Doyle said. Noting that the Vystar board is also considering the potential for Vystar to become a publicly traded...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.